Immuneering Corporation (IMRX)
| Market Cap | 275.61M +86.8% |
| Revenue (ttm) | n/a |
| Net Income | -54.44M |
| EPS | -1.06 |
| Shares Out | 64.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 460,464 |
| Open | 4.360 |
| Previous Close | 4.360 |
| Day's Range | 4.080 - 4.360 |
| 52-Week Range | 2.900 - 10.080 |
| Beta | 0.41 |
| Analysts | Strong Buy |
| Price Target | 18.86 (+342.72%) |
| Earnings Date | Aug 12, 2026 |
About IMRX
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinica... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for IMRX stock is "Strong Buy." The 12-month stock price target is $18.86, which is an increase of 342.72% from the latest price.
News
Immuneering publishes preclinical data on atebimetinib in Cancer Research
Immuneering (IMRX) announced the publication of new findings in Cancer Research, a journal of the American Association for Cancer Research, characterizing the mechanism and preclinical activity of ate...
Publication in Cancer Research Details Atebimetinib's Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has constraine...
Immuneering Corporation Announces Grants of Inducement Awards
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously ...
Immuneering initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Immuneering (IMRX) with an Overweight rating. Immuneering is developing a new class of deep cyclic inhibitors, with its lead MEK inhibitor atebimetinib advancin...
Immuneering appoints Andrew Gengos as CFO
Immuneering (IMRX) announced the appointment of Andrew Gengos as CFO, effective July 16. Gengos most recently served as CFO and head of corporate development at Terns Pharmaceuticals. At Immuneering, ...
Immuneering Appoints Andrew Gengos as Chief Financial Officer
- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Imm...
Immuneering Transcript: AGM 2026
The meeting covered director elections and auditor ratification, with both proposals approved. No questions were raised by stockholders, and final vote results will be published in a Form 8-K filing.
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone Topline data readout, including primary endp...
Immuneering announces updated clinical data from atebimetinib combination trial
Immuneering (IMRX) announced updated clinical data from its ongoing Phase 2a trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic d...
Immuneering Transcript: Study result
Phase II-A data for atebimetinib plus modified gemcitabine nab-paclitaxel in first-line pancreatic cancer show a median overall survival of 17.3 months with favorable tolerability and high rates of weight stability. The phase III MAPKeeper 301 trial is now recruiting, and the company is financially positioned to fund operations into 2029.
Immuneering Press release: Study result
Immuneering issued a press release on June 1, 2026, disclosing material business information to investors.
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Can
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
Immuneering reports Q1 EPS (21c), consensus (25c)
“We are excited that new survival data from 55 first-line pancreatic cancer patients treated with atebimetinib + mGnP in our Phase 2a clinical trial will be reported in an oral…
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
- New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer to be presented in an oral session at 2026 ASCO Annual Meeting - - Pivotal P...
Immuneering Earnings release: Q1 2026
Immuneering released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Immuneering Quarterly report: Q1 2026
Immuneering has published its Q1 2026 quarterly earnings report on May 15, 2026.
Immuneering announces updated data from Phase 2a trial for atebimetinib
Immuneering (IMRX) Corporation announced that updated data from the Phase 2a clinical trial evaluating atebimetinib, IMM-1-104, in combination with modified gemcitabine/nab-paclitaxel in first-line pa...
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health -
Immuneering announces presentation of new genetic data at 2026 AACR
Immuneering (IMRX) announced the presentation of new genetic data at the 2026 American Association for Cancer Research, AACR, Annual Meeting taking place April 17-22, 2026 in San Diego, CA. Key…
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alterations are rare, supporting observed durable first-line activity Atebimetinib-treated tumors rarel...
Immuneering Proxy statement: Proxy filing
Immuneering filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Immuneering Proxy statement: Proxy filing
Immuneering filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Immuneering Transcript: 25th Annual Needham Virtual Healthcare Conference
Atebimetinib demonstrated a 64% 12-month overall survival in first-line pancreatic cancer, nearly doubling the standard of care, with robust tolerability and unique mechanisms supporting survival. The ongoing phase III trial is fully funded, with first patient dosing expected mid-year and top-line results in about two years.
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today anno...